FDA Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients

NVO wins FDA's accelerated nod for a higher 7.2 mg Wegovy dose, backed by strong phase III weight-loss data, with a U.S. launch planned for April 2026.